Thus, our data suggest that MEK inhibition in 3D culture can partially restore sensitivity to therapeutic agents and that this may be particularly useful in the context of de novo endocrine-resistant ER+/Her2+ cancers. This evidence concerns the gene MAP2K7 and cancer.